Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Sandra Kanan, NP, RN, MSN, Ajay K Gopal, MD, Ryan D Cassaday, MD, Andrei R. Shustov, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Mazyar Shadman, MD MPH, Warren Houston, MD PhD, Melinda Tran, Pharm.D, Oliver Press, Stephen Smith, MD

Blood (2016) 128 (22): 3577.

https://doi.org/10.1182/blood.V128.22.3577.3577

Published: 2016

Journal Articles

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Ariela Noy, MD PhD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, MD, Christopher Flowers, MDMS, Franck Morschhauser, Graham P. Collins, MD PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD PhD, Robert W Chen, MD

Blood (2016) 128 (22): 1213.

https://doi.org/10.1182/blood.V128.22.1213.1213

Published: 2016

Journal Articles

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Allison Marie Winter, MD, Daniel J. Landsburg, MD, Francisco J. Hernandez-Ilizaliturri, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Smith, MD, Mazyar Shadman, Paolo Caimi, MD, Deepa Jagadeesh, MD MPH, Mitchell R. Smith, Brian T. Hill, MD PhD

Blood (2016) 128 (22): 1115.

https://doi.org/10.1182/blood.V128.22.1115.1115

Published: 2016

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Email alerts

ASH Publications

American Society of Hematology

Update search

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only